ArticleClinical ophthalmology (Auckland, N.Z.)2026
Faricimab versus Aflibercept for Discharge and Readmission in Neovascular Age-Related Macular Degeneration: A Lesion-Type Stratified, Real-World UK Analysis.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-VEGF treatment improves outcomes in neovascular age-related macular degeneration (nAMD) management. No real-world data have compared discharge and readmission rates between Faricimab and Aflibercept 2mg, stratified by lesion type. Methods: A retrospective audit study of 1004 eyes in 912 patients diagnosed with nAMD. Patients received either Faricimab or Aflibercept 2mg. The outcomes assessed were central macular thickness CMT, best-corrected visual acuity BCVA, fluid resolution, discharge to community care defined as being asymptomatic for more than 6 months and then reviewed by optometrist, and readmission. Lesion types were classified into Type 1, Type 2, and Prepapillary. Statistical analysis used Results: The demographic of the patients in this study consisted of 60.6% of women with participants being on average 76.9 years old. Type 1 lesions had a greater change from baseline CMT, and a greater change in BCVA than Type 2 lesions. Discharge rates from hospital and the average time to discharge from hospital was greater for Faricimab (84.1%, 378 days) compared with Aflibercept (69.5%, 1048 days, p < 0.0001). The number of eyes readmitted was lower for Faricimab (14.7% vs 29.1%) and was not different for lesion type (p = 0.96). The number of injections was not different amongst discharged patients and readmitted patients. In this retrospective cohort, service outcomes at discharge and readmission appeared to differ between Faricimab and aflibercept, whereas no clear differences were observed by lesion type. Conclusion: In this real-world audit, treatment with Faricimab was associated with higher discharge rates, earlier discharge, and fewer readmissions compared with aflibercept, although these findings should be interpreted as observational associations rather than causal effects. Lesion type did not appear to be an independent predictor of these service outcomes within the limits of this analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.